Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Article excerpt
Highlighted: the sentence this signal was extracted from
NEW BRUNSWICK, N.J., Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced positive results from a Phase 3 study investigating ICOTYDE ® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA). a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor. 1 ICOTYDE met the primary endpoint, with 58% of patients achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo at Week 16. 2 Safety findings were consistent with the established safety profile of ICOTYDE, with no new safety signals identified. These results are being presented as a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2026. Psoriatic arthritis is a chronic, immune-mediated inflammatory disease that can affect both the joints and skin. 3,4 Nearly 30 percent of people with plaque psoriasis also develop psoriatic arthritis. 5,6 It can cause pain, stiffness and swelling in and around the joints, along with the skin lesions associated with plaque psoriasis. 7 Because inflammation can lead to progressive disease, there remains a need for treatment approaches that address the multiple ways psoriatic arthritis can affect patients. In clinical studies, ACR response is a composite measure whereby ACR20 represents ≥20% improvement in tender joint count, swollen joint...
Keep reading with a free account
The rest of this article, and every signal for Johnson & Johnson, is in your free account.
